Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psilocybin: from ancient magic to modern medicine
David E. Nichols
The Journal of Antibiotics (2020) Vol. 73, Iss. 10, pp. 679-686
Closed Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

The Therapeutic Potential of Psilocybin
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Molecules (2021) Vol. 26, Iss. 10, pp. 2948-2948
Open Access | Times Cited: 156
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
Stephanie Knatz Peck, Samantha Shao, Tessa Gruen, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 1947-1953
Open Access | Times Cited: 70
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
Mind the mushroom: natural product biosynthetic genes and enzymes of Basidiomycota
Markus Gressler, Nikolai A. Löhr, Tim Schäfer, et al.
Natural Product Reports (2021) Vol. 38, Iss. 4, pp. 702-722
Closed Access | Times Cited: 78
Psilocybin and MDMA for the treatment of trauma-related psychopathology
Catherine Bird, Nadav Liam Modlin, James Rucker
International Review of Psychiatry (2021) Vol. 33, Iss. 3, pp. 229-249
Open Access | Times Cited: 63
Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
Grant C. Glatfelter, Eline Pottie, John S. Partilla, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 11, pp. 1181-1196
Open Access | Times Cited: 55
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1945-1976
Open Access | Times Cited: 52
Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients
Sarah Shnayder, Rezvan Ameli, Ninet Sinaii, et al.
Journal of Affective Disorders (2022) Vol. 323, pp. 592-597
Closed Access | Times Cited: 43
Antioxidant, Antimicrobial Activities, Total Phenolic and Element Contents of Wild Edible Mushroom Bovista nigrescens
Celal Bal, Emre Cem Eraslan, Мustafa Sevindik
Prospects in Pharmaceutical Sciences (2023) Vol. 21, Iss. 2, pp. 37-41
Open Access | Times Cited: 26
Psilocybin Exposures Reported to U.S. Poison Centers: National Trends Over a Decade
Rita Farah, Abigail F. Kerns, A. C. MURRAY, et al.
Journal of Adolescent Health (2024) Vol. 74, Iss. 5, pp. 1053-1056
Closed Access | Times Cited: 9
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e121-e132
Closed Access | Times Cited: 9
Biosynthesis and synthetic biology of psychoactive natural products
Cooper S. Jamieson, Joshua Misa, Yi Tang, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 12, pp. 6950-7008
Open Access | Times Cited: 51
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2520-2520
Open Access | Times Cited: 33
Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology
Rebecca Smausz, Joanna C. Neill, John Gigg
Journal of Psychopharmacology (2022) Vol. 36, Iss. 7, pp. 781-793
Open Access | Times Cited: 33
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality
Grant Jones, Matthew K. Nock
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 31
Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder
Manish Agrawal, William A. Richards, Yvan Beaussant, et al.
Cancer (2023) Vol. 130, Iss. 7, pp. 1137-1146
Closed Access | Times Cited: 21
Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor
Ram Harari, Ipsita Chatterjee, Dmitriy Getselter, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109686-109686
Open Access | Times Cited: 6
The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health
Sam Gandy, Matthias Forstmann, Robin Carhart‐Harris, et al.
Health Psychology Open (2020) Vol. 7, Iss. 2
Open Access | Times Cited: 47
Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy
Sascha Thal, Stephen Bright, Jason M. Sharbanee, et al.
Frontiers in Psychology (2021) Vol. 12
Open Access | Times Cited: 35
Genetic Survey of Psilocybe Natural Products
Sebastian Dörner, Kai Rogge, Janis Fricke, et al.
ChemBioChem (2022) Vol. 23, Iss. 14
Open Access | Times Cited: 25
Psilocybin’s effects on cognition and creativity: A scoping review
Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 635-648
Open Access | Times Cited: 15
A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond
Marco Pepe, Mohsen Hesami, Karla A. de la Cerda, et al.
Biotechnology Advances (2023) Vol. 69, pp. 108247-108247
Closed Access | Times Cited: 14
Psilocybin history, action and reaction: A narrative clinical review
Pravesh Sharma, Quang A. Nguyen, Sadie J. Matthews, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 849-865
Closed Access | Times Cited: 13
Edible Mushrooms: a Nutrient-Rich Ingredient for Healthier Food Products – A Review
Carolina Losoya‐Sifuentes, Mario Cruz, María del Refugio Rocha-Pizaña, et al.
Current Nutrition Reports (2025) Vol. 14, Iss. 1
Closed Access
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review
Joshua Liebnau, Felix Betzler, André Kerber
Journal of Psychopharmacology (2025)
Open Access
Page 1 - Next Page

Scroll to top